TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy

Introduction. Liver biopsy is an invasive determinator for hepatic fibrosis. Serum biomarkers can probably be used as an alternative to liver biopsy in assessment of the degree of fibrosis in patients with chronic Hepatitis C. Method. Eighty patients with chronic Hepatitis C were included in the study using simple nonrandom sampeling metod. After fulfillment of liver biopsy, the patients were categorized according to the METAVIR Scoring system. The Hepascore algorithm is computed based on age, sex, and the serum levels of total bilirubin, -glutamyl transferase, 2-Macroglobulin, and hyaluronic acid. The spearman and ROC tests were used. Results. According to the liver biopsy results, 12, 25, 20, 7 and 16 patients had F0, F1, F2, F3, and F4, respectively. With regard to the 0.34 cut-off point Hepascore had 67%, 56%, 64%, and 56% sensitivity, specificity, respectively, positive prediction value (PPV), and negative prediction value (NPV), respectively, for diagnosis of significant fibrosis. For a Hepascore cut-off point 0.61, sensitivity, specificity, respectively, PPV and NPB 82%, 86%, 70%, and 92% in diagnosis of severe fibrosis. For a Hepascore cut-off point 0.84, sensitivity, specificity, PPV and NPB were respectively 100%, 97%, 89%, and 100% for diagnosis of cirrhosis. Conclusion. Hepascore has a high value in diagnosis of the level of fibrosis, particularly cirrhosis. Therefore, it can be used for primary screening of patients to determine the need for liver biopsy.

Download Full-text

Association of Hepcidin mRNA Expression With Hepatocyte Iron Accumulation and Effects of Antiviral Therapy in Chronic Hepatitis C Infection

Hepatitis Monthly ◽

10.5812/hepatmon.21184 ◽

2014 ◽

Vol 14 (10) ◽

Cited By ~ 9

Author(s):

Katarzyna Sikorska ◽

Tomasz Romanowski ◽

Piotr Stalke ◽

Ewa Izycka Swieszewska ◽

Krzysztof Piotr Bielawski

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Mrna Expression ◽

Antiviral Therapy ◽

Chronic Hepatitis C ◽

Iron Accumulation ◽

Hepatitis C Infection ◽

Hepcidin Mrna

Download Full-text

Significance of serum WFA+-M2BP level as a marker of liver fibrosis in patients with chronic hepatitis C

Infekcionnye bolezni ◽

10.20953/1729-9225-2020-4-80-84 ◽

2020 ◽

Vol 18 (4) ◽

pp. 80-84

Author(s):

N.N. Volkova ◽

◽

N.S. Ibadullaeva ◽

M.U. Asilova ◽

E.I. Musabaev ◽

...

Keyword(s):

Liver Cirrhosis ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Liver Fibrosis ◽

Antiviral Therapy ◽

Chronic Hepatitis C ◽

Treatment Initiation ◽

Serum Levels ◽

Serum Marker

Objective. To evaluate the role of dynamics of WFA+-M2BP, a serum marker of liver fibrosis, in patients with chronic hepatitis C (CHC). Patients and methods. We examined 56 CHC patients who received antiviral therapy. The severity of liver fibrosis was assessed using indirect elastometry. There were 8 patients with F0 fibrosis, 17 patients with F1 fibrosis, 6 patients with F2 fibrosis, 12 patients with F3 fibrosis, and 13 patients with F4 fibrosis. The level of WFA+-M2BP was measured prior to treatment initiation, then 1 month after treatment initiation, and 3 months after treatment completion. Results. We found that both CHC patients and patients with HCV-induced liver cirrhosis demonstrated a decrease in the serum level of WFA+-M2BP in response to antiviral therapy. Mean levels of WFA+-M2BP in individuals with F3 and F4 fibrosis were significantly higher than those in patients with F0 fibrosis (p < 0.01). Conclusion. Higher grades of liver cirrhosis were associated with higher serum levels of WFA+-M2BP, while antiviral therapy led to a decrease in the concentration of this biomarker. The assessment of WFA+-M2BP dynamics will help to detect early stages of liver fibrosis and also to monitor it in patients receiving antiviral therapy. Key words: chronic hepatitis C, liver cirrhosis caused by HCV, biomarker, WFA+-M2BP, liver fibrosis, antiviral therapy

Download Full-text

Comparative Histologic Features of Liver Biopsy Specimens From Patients Coinfected With Hepatitis G and C Viruses With Chronic Hepatitis C Virus Alone:An Age-, Sex-, Disease Duration–, and Transmission-Matched Controlled Study of Chronic Hepatitis

American Journal of Clinical Pathology ◽

10.1093/ajcp/108.6.625 ◽

1997 ◽

Vol 108 (6) ◽

pp. 625-632 ◽

Cited By ~ 4

Author(s):

Neal S. Goldstein ◽

Jeanette Underhill ◽

Stuart C. Gordon ◽

Nasser Bayati ◽

Ann Silverman

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Liver Biopsy ◽

Chronic Hepatitis C ◽

Disease Duration ◽

Controlled Study ◽

Biopsy Specimens ◽

Chronic Hepatitis C Virus ◽

Hepatitis G

Download Full-text

Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy

Clinical & Investigative Medicine ◽

10.25011/cim.v32i3.6110 ◽

2009 ◽

Vol 32 (3) ◽

pp. 212 ◽

Cited By ~ 10

Author(s):

Katia Falasca ◽

Paola Mancino ◽

Claudio Ucciferri ◽

Margherita Dalessandro ◽

Lamberto Manzoli ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Antiviral Therapy ◽

Chronic Hepatitis C ◽

Ferritin Level ◽

Serum Levels ◽

Hcv Rna ◽

Depression Symptoms

Purpose: To evaluate the effect of chronic hepatitis C and antiviral therapy on health-related quality of life (HRQoL), depression symptoms and cytokine patterns. Methods: Twenty HCV+ patients treated with peginterferon plus ribavirin were enrolled in this cohort study and invited to complete SF-12 and BDI questionnaires prior to (T0) and at the end of the treatment (T1). HCV-RNA, serum levels of ALT, AST, haemoglobin, ferritin and IFN-?, TNF-?, IL-2, IL-4, IL-6 and IL-10 were evaluated at T0 and T1. The questionnaire results were correlated to biochemical and cytokine parameters. Results: Two patients (1%) dropped out and 18 HCV patients composed the final sample (11 males (61.1%); mean age 42.5±11.9 yr; mean disease duration 9.7±6.9 yr). Between T0 and T1 ALT (p=0.02), AST (p=0.052) HCV-RNA (P=0.0002) and haemoglobin levels decreased (p=0.0003), whereas ferritin level increased (P=0.003). Also, at T1 all cytokine levels were augmented. Regarding depression status, at T0 10 patients (55.5%) scored above to the BDI questionnaire (suggesting clinically significant depression), whereas at T1 14 patients scored 10 or above (77.7%). At T1 the mean BDI score increased, but this difference was not significant. Regarding HRQoL, the majority of patients had T0 summary scores ? 50. At T1 HRQoL changed and scores decreased in 66.7% of the patients. A correlation was observed between the T0 level of ferritin and the amount of change in BDI and SF-12 mental score between T0 and T1 (Spearman rho = -0.56 and +0.61, respectively) and IL-4 level at T0 and the change in BDI and SF-12 mental scores (Spearman rho = -0.49 and +0.45, respectively). Conclusion: BDI, SF-12, IL-4 and ferritin are good tools to predict the appearance of depressive symptoms and worsening of the quality of life in the HCV+ population.

Download Full-text

Soluble CD30 serum levels before and after treatment with α-interferon in patients with chronic hepatitis C

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm.2005.138 ◽

2005 ◽

Vol 43 (8) ◽

Author(s):

Enrico Di Cesare ◽

Aldo Spadaro ◽

Antonino Ajello ◽

Oscar Ferraù ◽

Nunziata Alessi ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Activity Index ◽

Serum Levels ◽

Soluble Cd30 ◽

Before And After ◽

The Difference ◽

Ifn Treatment ◽

Histology Activity Index

AbstractIt has been suggested that soluble CD30 (sCD30) serum levels in chronic hepatitis C are correlated with the activity of the disease and with the outcome of interferon (IFN) treatment. In this study, sCD30 serum levels in 25 patients with chronic hepatitis C, before and after treatment with IFN-2α, were measured. A total of 20 healthy subjects were used as controls. High sCD30 levels in serum were found in 36% of patients and in 5% of controls. In patients with sCD30 levels above or within the normal range, no significant differences in age, gender, serum transaminases and histology activity index were found. In relation to IFN treatment, only responder patients had serum sCD30 higher than controls, although the difference between responders and non-responders was not significant. No changes from baseline values were observed after treatment. Although high, sCD30 serum levels in chronic hepatitis C are not correlated with the disease activity, are not affected by IFN treatment and are not predictors of response to IFN treatment.

Download Full-text